AbbVie price target lowered to $212 from $221 at Guggenheim
Guggenheim analyst Vamil Divan lowered the firm’s price target on AbbVie (ABBV) to $212 from $221 and keeps a Buy rating on the shares. The ...
AbbVie CEO says psychiatric drug space challenging, more cautious on investments
AbbVie will commit less capital towards experimental medicines for psychiatric disease, CEO Robert Michael said at an ...
Quotidianosanità.it14d
Epatite C. Nuovi farmaci “interferon free” solo per pochi. Aifa fissa i criteri per l’accesso. Ecco chi potrà accedervi e a chi rivolgersi
Tale accesso per uso nominale è aperto a tutti i pazienti, per le cui richieste di trattamento i centri non inclusi nella lista allegata potranno contattare la Direzione Medica di AbbVie srl”.
BioSpace14d
AbbVie to Host Full-Year and Fourth-Quarter 2024 Earnings Conference Call
AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable ...
Esame21d
Cos’è una SRL, come funziona e come costituirla
Creare una società a responsabilità limitata (SRL) è una scelta strategica per molti imprenditori, grazie alla flessibilità gestionale e alla tutela patrimoniale offerta da questa forma giuridica. Ma ...
Business Standard23d
Action likely against AbbVie executive who signed self-declaration
American drug major AbbVie Healthcare’s Indian arm, which is under the scanner for sponsoring foreign trips of 30 doctors in violation of the Uniform Code for Pharmaceutical Marketing Practices (UCPMP ...
Pharmaceutical Technology23d
ABBV-932 by AbbVie for Schizophrenia: Likelihood of Approval
ABBV-932 is under clinical development by AbbVie and currently in Phase I for Schizophrenia. According to GlobalData, Phase I drugs for Schizophrenia have a 66% phase transition success rate (PTSR) ...
Business Line24d
Apex Committee for Pharma Marketing Practices finds Abbvie in violation of ethics code
The Apex Committee for Pharma Marketing Practices has found Abbvie Healthcare India Private Ltd in breach of the UCPMP ( Uniform Code for Pharmaceutical Marketing Practices), by sponsoring ...
Indiatimes24d
AbbVie Healthcare under government lens for 'violations'
The department of pharmaceuticals (DoP) reprimanded AbbVie Healthcare India for unethical marketing practices involving over ₹1 crore spent on foreign vacations for 30 doctors under the guise of ...
Nasdaq25d
Is AbbVie Stock a Buy?
With its shares offering a total return of nearly 49% over the last three years, trumping the market's return of 33%, AbbVie (NYSE: ABBV) is a powerhouse big pharma that has a lot of upside to ...
The Motley Fool25d
Is AbbVie Stock a Buy?
AbbVie has a solid medium-term growth plan and the means to accomplish it. Acquisitions and licensing deals could make for unexpected upsides. Still, its shares aren't priced inexpensively at the ...
Yahoo Finance25d
AbbVie (ABBV) Benefitted from Top-Line Growth From Its Immunosuppressive Drugs
Polaris Global Equity Strategy highlighted stocks like AbbVie Inc. (NYSE:ABBV) in its Q3 2024 investor letter. AbbVie Inc. (NYSE:ABBV) discovers, develops, manufactures, and sells pharmaceuticals.